Do ta filloj prezantimin në vitin e largët 1989 kur unë jetoja me familjen time bashkë në Bulqizë dhe ë lodra ime e parë, dhurata e parë që më bëhet ë është mundësia për të pasur një karrocë prej këtyre që ishin karrocën në kushinetën në atë kohë ë pata mundësinë që ta ndërtoj bashkë me babain tim dhe me shokët e tij, pasi ai kishte një dyqan, një ë ë magazinë ku shiste pjesë këmbimi. Ishin të shtetit normalisht, pasi në atë kohë nuk kishte dyqane private. Ë u aposionova shumë mbas kësaj pasi ishte ndërtuar ...

转自：新华财经 以"汇新智・促转化・共筑国际健康创新生态"为主题的第七届健康中国・思南对话9月28日在沪举办，来自政府部门、科研机构、医疗机构、产业主体及投 资领域的代表汇聚一堂，聚焦生物医药创新转化与国际合作重点方向，共同研究谋划产业发展新路径。 上海市黄浦区委书记杲云在致辞中表示，将强化广慈-思南园区的平台功能，构建以数字科技和生命健康为核心的"2+1"现代产业体系。他特别提及世博浦西 片区"中央科创区"规划，称该区域以数字科技、生命健康为核心产业方向，将打造全球创新要素融汇之地，诚邀企业英才扎根发展。 中国工程院院士、瑞金医院院长宁光介绍，瑞金医院联合黄浦区共建广慈—思南园区，推动多领域跨界融合，国产首台套质子治疗装置、开源病理大模型等 标志性成果已成功落地。未来，医院将深化"医产学研企"协同，主动融入黄浦中央科创区建设。 为推动理念落地，本次会议举行了八大发布与签约环节，涵盖生态构建、人才保障、技术创新等关键领域。黄浦区与瑞金医院共同启动了"广慈思南（中港 汇）医学转化创新生态发布仪式"；"园区人才企业年金计划"启航，成为了上海市同类政策在黄浦区及国家级园区的首次落地，彰显了引才留才决心；"瑞金 医学 ...

Core Viewpoint - Guerbet has appointed Mr. Jérôme Estampes as interim Chief Executive Officer, succeeding Mr. David Hale, who is leaving the company to pursue new projects [2][3]. Company Management Changes - Mr. Jérôme Estampes has been with Guerbet since 2019 as Chief Administrative and Financial Officer, where he has developed a strong understanding of the company's financial, operational, and commercial challenges [3]. - The Board of Directors has expressed gratitude to Mr. David Hale for his contributions since joining in February 2018, first as Chief Commercial Officer and then as CEO from January 1, 2020 [2][4]. Transition and Future Leadership - The Board supports Mr. Estampes and he will have the assistance of Guerbet's Executive Committee to ensure a smooth transition and to continue implementing transformation measures and the commercial strategy [4]. - The Nominations and Remuneration Committee has initiated the recruitment process for a permanent Chief Executive Officer [4]. Company Overview - Guerbet is a global leader in medical imaging, focusing on improving patient care through innovation, with nearly a century of expertise [6]. - The company offers a comprehensive portfolio of pharmaceutical products, medical devices, and AI-driven solutions for diagnostic and interventional imaging [6]. - Guerbet invests 10% of its annual revenue in research and development and reported €786 million in revenue in 2023 [6].

Company Leadership - Penumbra, Inc. has announced the promotion of Shruthi Narayan to President, effective September 1, 2025, while Adam Elsesser continues as chairman and CEO [1] - Shruthi Narayan is recognized as a dynamic leader with a strong background in innovation and team inspiration, which is expected to support Penumbra's growth and market leadership [2] Professional Background - Ms. Narayan has 20 years of experience in the medical device industry, previously serving as president of Penumbra's interventional business, overseeing growth initiatives in neuro and vascular franchises [2] - She joined Penumbra in 2013 as a product manager and has played a significant role in building the company's vascular division and commercializing its thrombectomy products globally [2][3] - Narayan holds a B.S. in Electrical Engineering from Anna University, India, and an M.S. in Biomedical Engineering from the University of Southern California, focusing on Medical Device Commercialization [3] Company Overview - Penumbra, Inc. is a leading thrombectomy company focused on innovative technologies for medical conditions such as ischemic stroke and pulmonary embolism [4] - The company offers a broad portfolio, including computer-assisted vacuum thrombectomy (CAVT), aimed at improving patient outcomes and quality of life in over 100 countries [4]

Core Insights - AngioDynamics (ANGO) is experiencing growth driven by its NanoKnife product and a focus on cancer treatment markets, supported by a strong fourth-quarter fiscal 2025 performance and ongoing studies [1][6][10] - The company's shares have seen a slight decline of 0.3% year-to-date, contrasting with a 7% decline in the industry and an 8.8% increase in the S&P 500 [1][2] Company Performance - AngioDynamics has a market capitalization of $358.8 million and projects a 50% growth over the next year, with earnings surpassing the Zacks Consensus Estimate in the last four quarters, averaging a surprise of 72.58% [2][3] - The fourth-quarter fiscal 2025 results showed a narrower adjusted loss per share and revenues exceeding expectations, indicating strong execution across both operating segments [11] Product and Market Dynamics - The NanoKnife product, which received FDA clearance and Breakthrough Device Designation, generated total revenues of $24.5 million in fiscal 2025, with fourth-quarter revenues of $7.2 million reflecting growth in disposable sales despite softer capital placements [3][4] - Recurring disposable sales grew by 9.6% for the year, providing a reliable revenue stream to offset variability in system placements [3] Clinical and Product Development - AngioDynamics is advancing a broad pipeline of clinical studies, including the AMBITION trial for Auryon and the RECOVER-AV trial for AlphaVac, aimed at enhancing its market position [7][8] - The NanoKnife's PRESERVE prostate trial has met primary endpoints, paving the way for reimbursement catalysts starting in 2026 [8] Financial Outlook - The company anticipates gross margins in the range of 53.5% to 55.5% for fiscal 2026, with adjusted EBITDA projected between $3.0 million and $8.0 million [13] - However, there has been a negative estimate revision trend for fiscal 2026, with the consensus estimate for loss per share expanding from 6 cents to 30 cents [14]

The Prototype: This Startup Aims To Grow New Mini-Organs In Patientshttps://t.co/HGbErnSgBM https://t.co/jtOvNGOWKl ...

Company Overview - Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases with unmet medical needs [4] - The company is advancing its HyBryte(TM) platform, a novel therapy for treating cutaneous T-cell lymphoma (CTCL), primarily affecting older adults [3][4] - Successful U.S.-based manufacturing of HyBryte's active ingredient has been established, positioning the company for significant impact in the healthcare sector [3] Product Development - The Specialized BioTherapeutics segment is moving towards potential commercialization of HyBryte(TM) after completing the second Phase 3 study, with regulatory approvals anticipated [4] - Other development programs include synthetic hypericin (SGX302) for psoriasis, and dusquetide (SGX942) for inflammatory diseases, including oral mucositis in head and neck cancer [4] - The Public Health Solutions segment includes vaccine candidates such as RiVax(R) for ricin toxin, and CiVax(TM) for COVID-19, supported by government grants and contracts [5] Market Context - The aging U.S. population is facing increasing challenges from chronic and rare diseases, with over 30 million Americans affected by rare diseases [2] - The Trump administration's initiatives aim to improve access to treatments and accelerate medical innovation in response to this healthcare crisis [2]

Innovation Landscape - China has emerged as the second engine of innovation globally, although the US remains the leader in the field [1] - There's a substantial return of scientists to China from the US and the UK, driven by opportunities and capital investment [2] - The Chinese government facilitates the return of scientists by providing money and capital for investment [2] Talent Migration - Some scientists are reportedly leaving the United States due to policy concerns [1] - Scientists are moving to China because of opportunities to create companies, secure funding, and take risks [3] - Many scientists working with biotech companies in China are American-Chinese, frequently bridging the US and China [2][3] Competitive Advantage - China offers opportunities to create companies, be funded, and take risks, leading to success for many [3] - The US needs to maintain its leadership in innovation [3]

Industry Innovation & Competition - Chinese biotech companies are developing numerous drugs similar to Ompic, potentially challenging US and EU medical advancements [1] - China is playing an increasingly significant role in developing innovative medicines for serious diseases like cancer and cardiovascular conditions [2] - Chinese drug makers are studying a significantly higher number of new drug candidates compared to the EU and are approaching the US in this regard [2] - An increasing number of Chinese drugs are demonstrating sufficient quality to be fast-tracked by major Western regulators [3] - A Chinese drug outperformed a US company's world-leading cancer drug in a study last year [3] US-China Tech Rivalry & Market Dynamics - The US-China tech rivalry is extending to the medical innovation field [4] - Big pharma companies are investing heavily in acquiring Chinese medical innovations for US and European markets [4] - Some Chinese drugs are already available in US and European markets [4]

Innovation & R&D - The US leads the world in life science innovation due to a combination of factors including investment in basic research, venture capital, strong companies, and protection of intellectual property [3][5] - Big Pharma increasingly relies on external innovation, with internal drug development accounting for less than 30% of FDA approvals between 2015 and 2021 [11] - AI and machine learning are accelerating drug discovery by enabling the screening of 1.7 million compounds in approximately 5-10 days, significantly reducing the time required for identifying lead compounds [3][14][15] Investment & Finance - In 2021, the pharmaceutical industry invested over $80 billion annually in R&D, a tenfold increase over 10 years, representing approximately 25% of pharma companies' revenues [4] - Venture capital firms investing in biotech require patience, with a time horizon of 10-15 years to see a drug from discovery to commercialization [13] - New Jersey offers an R&D tax credit to attract big pharma companies and has a program allowing early-stage life sciences companies to monetize their net operating losses [20][21] Company Strategy & Focus - Johnson & Johnson (J&J) has invested $50 billion in R&D and M&A since the beginning of last year [10] - J&J actively scouts the world for promising innovations and technologies to leverage its scale in research, development, manufacturing, and commercialization [6] - J&J is developing an oral medicine, icotrokinra, to treat plaque psoriasis, which is expected to be a significant breakthrough and contribute to growth in the second half of the decade [7][9]